Article
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
Cancer immunology, immunotherapy : CII - 1 Sept 2015
Anastasopoulou Eleftheria A, Voutsas Ioannis F, Keramitsoglou Theodora, Gouttefangeas Cécile, Kalbacher Hubert, Thanos Anastasios, Papamichail Michael, Perez Sonia A, Baxevanis Constantin N
Abstract excerpt
Recently, several types of immunotherapies have been shown to induce encouraging clinical results, though in a restricted number of patients. Consequently, there is a need to identify immune biomarkers to select patients who will benefit from such therapies. Such predictive biomarkers may be also used as surrogates for overall survival (OS). We have recently found correlations between immunologic parameters and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.